Vericel (VCEL) Stock Climbs on Solid Phase 2b Data!

By |March 11th, 2016|

Vericel Corp (NASDAQ: VCEL)

Vericel is having an incredible day in the market today after a key announcement the company made yesterday. The announcement surrounded one of the company’s lead drug candidates and the results of that candidate in Phase 2b trials. Today, we’ll take a look at the results, how the market reacted to […]